Danaher Corporation (NYSE:DHR) Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. increased its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 14.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,261,196 shares of the conglomerate's stock after buying an additional 155,537 shares during the quarter. Envestnet Asset Management Inc. owned about 0.18% of Danaher worth $258,545,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in DHR. Fortis Capital Advisors LLC increased its position in shares of Danaher by 1.3% during the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after acquiring an additional 50 shares during the period. Fayez Sarofim & Co boosted its stake in shares of Danaher by 0.6% during the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after buying an additional 50 shares during the period. Coastal Bridge Advisors LLC boosted its stake in shares of Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock worth $252,000 after buying an additional 50 shares during the period. Perennial Investment Advisors LLC lifted its position in Danaher by 2.2% in the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after purchasing an additional 51 shares during the period. Finally, Sound View Wealth Advisors Group LLC increased its holdings in Danaher by 3.1% in the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock valued at $399,000 after buying an additional 52 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Stock Down 0.3%

Shares of NYSE:DHR traded down $0.71 during midday trading on Friday, reaching $204.80. The company's stock had a trading volume of 2,369,010 shares, compared to its average volume of 3,504,283. The firm has a market capitalization of $146.57 billion, a P/E ratio of 39.77, a PEG ratio of 2.89 and a beta of 0.77. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $281.70. The firm has a 50 day moving average of $196.05 and a 200-day moving average of $206.47.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The firm had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.58 billion. On average, research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.63%. Danaher's dividend payout ratio (DPR) is currently 24.85%.

Analyst Ratings Changes

A number of analysts recently issued reports on DHR shares. Jefferies Financial Group decreased their target price on shares of Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a research report on Tuesday, April 22nd. Bank of America lowered their price objective on Danaher from $265.00 to $230.00 in a research note on Monday, April 14th. Deutsche Bank Aktiengesellschaft reduced their target price on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Citigroup reaffirmed a "buy" rating on shares of Danaher in a report on Monday, April 7th. Finally, Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a report on Friday. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, Danaher currently has an average rating of "Moderate Buy" and an average target price of $248.43.

Insiders Place Their Bets

In related news, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman directly owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president directly owned 15,179 shares of the company's stock, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.10% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.